Advertisement
U.S. markets open in 4 hours 47 minutes

Lumos Pharma, Inc. (LUMO)

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
3.0000-0.0500 (-1.64%)
At close: 04:00PM EST
3.0000 0.00 (0.00%)
Pre-Market: 04:00AM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Previous Close3.0500
Open2.9400
Bid2.8000 x 1000
Ask3.8000 x 2200
Day's Range2.9300 - 3.0500
52 Week Range2.6300 - 4.5500
Volume11,403
Avg. Volume21,920
Market Cap23.744M
Beta (5Y Monthly)0.36
PE Ratio (TTM)N/A
EPS (TTM)-3.9900
Earnings DateMar 07, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est22.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for LUMO

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Lumos Pharma, Inc.
    Analyst Report: Pfizer Inc.Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
    Rating
    Fair Value
    Economic Moat
    3 days agoMorningstar
View more
  • GlobeNewswire

    Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024

    AUSTIN, Texas, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced it will report its full year 2023 financial results after market close on Thursday, March 7, 2024. The company will host a conference call and webcast at 4:30 PM ET that day to discuss these financial results and provide an update on clinical and corporate ac

  • GlobeNewswire

    Lumos Pharma to Participate in Oppenheimer’s 34th Annual Healthcare Life Sciences Conference

    AUSTIN, Texas, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for moderate Pediatric Growth Hormone Deficiency (PGHD), announced today that the Company will participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference, to be held virtually February 13-14, 2024. Lumos Pharma’s management will present and host virtual one-on-one meetings with the investment community on Wednesday, February 14

  • Simply Wall St.

    Is Lumos Pharma (NASDAQ:LUMO) In A Good Position To Invest In Growth?

    Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...